Target intelligence / Profile preview

TUSC2 pseudogene 1 (TUSC2P1)

Target
TUSC2P1
Molecular classification
Pseudogene, Non-coding RNA, Competing endogenous RNA (ceRNA), Other
01

Overview

TUSC2 pseudogene 1 (TUSC2P1), also known as TUSC2P, is a non-coding pseudogene highly homologous to the 3′-UTR of the tumor suppressor candidate gene TUSC2 (also called FUS1). TUSC2P1 does not encode a protein, but instead functions by binding and sequestering microRNAs (miRNAs) that would otherwise suppress TUSC2 mRNA, thereby indirectly modulating TUSC2 protein levels. Expression of TUSC2P1 has been shown to inhibit cancer cell proliferation, migration, invasion, and colony formation, mainly through this miRNA decoy function. TUSC2P1 may also regulate other target genes sharing similar miRNA binding sites, such as TIMP2 and TIMP3. Reduced TUSC2P1 expression has been linked with increased malignancy in several cancer cell types. While TUSC2 (the canonical gene) is sometimes a therapeutic target or biomarker, TUSC2P1 is a regulatory pseudogene and not itself considered a direct therapeutic target or druggable protein [4].

Other names
TUSC2PTUSC2 pseudogenelung cancer candidate FUS1 pseudogenetumor suppressor candidate 2 pseudogene 1TUSC2P1
02

Biological functions

Acts as a competing endogenous RNA (ceRNA) to regulate microRNA (miRNA) function and thus modulate expression of the protein-coding gene TUSC2 and other miRNA targets
03

Disease associations

Cancer (especially loss of TUSC2P1 transcription associated with breast and other human cancers)
04

Biomarkers

Loss of TUSC2P1 expression may correlate with malignant transformation in breast and other cancers, but not clinically established as a biomarker

Beyond the preview

Go deeper on TUSC2 pseudogene 1 (TUSC2P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TUSC2 pseudogene 1 (TUSC2P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call